Acticor Biotech
Patricia Zilliox, Ph.D. in Pharmacy, managed the ophthalmology clinical development programs as Senior Director Clinical Pharma at Alcon Laboratories in the US until 2011. Most recently, Patricia was responsible for identifying, funding and developing promising treatments for gene mutated retinal diseases at the Clinical Research Institute, a division of the Foundation Fighting Blindness, in Columbia, Maryland. Since 2017, she has been President and CEO of Eyevensys, a biotech company developing a non-viral gene therapy platform for the treatment of retinal diseases.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Acticor Biotech
Acticor Biotech is a spin-off from Inserm (French National Institute of Health and Medical Research) dedicated to the development of an innovative therapeutic strategy for safe and effective emergency treatment of ischemic strokes which account for 80% of all strokes.